North America Market Study on Ignition Interlock
Devices: Increasing Incidences of DUI to Catalyze
IID Demand in North America
R e s e a r c h
Report Media Releases
Global Lysosomal Storage Diseases Therapeutics Market
to Register a CAGR of 10.0% Between 2016 and 2026;
Europe Likely to be the Dominant Regional Market
Persistence Market Research delivers key insights on the global lysosomal storage diseases
therapeutics market in a new report titled, “Lysosomal Storage Diseases Therapeutics
Market: Global Industry Analysis and Forecast, 2016–2026”. In terms of revenue, the global
M a r k e t
lysosomal storage diseases therapeutics market is projected to register a healthy CAGR of
10.0% over the forecast period and is estimated to be valued at US$ 14.36 Bn by 2026. In the
report, Persistence Market Research analyzes the key factors and trends impacting the growth
and performance of the global lysosomal storage diseases therapeutics market over the forecast
period.
Drivers and trends influencing the market
An increasing diagnosis rate due to increasing awareness and financial incentives for orphan
drug development to recover R&D costs is the primary factor fueling the growth of the global
lysosomal storage diseases therapeutics market. Also, an increasing focus of major
P e r s i s t e n c e
biopharmaceutical companies on the research and development of drugs for the treatment of
rare diseases is expected to boost the global lysosomal storage diseases therapeutics market
during the forecast period. Moreover, the number of treatment options currently in the pipeline is
further expected to bolster revenue growth of the global lysosomal storage diseases therapeutics
market during the forecast period.
However, heterogeneity of the disease leading to underdiagnoses of lysosomal storage
diseases, lack of treatment options, and high cost of treatment are factors likely to hamper the
growth of the global lysosomal storage diseases therapeutics market over the forecast period.
Download Report Table of Content, Figures, and Tables @
http://www.persistencemarketresearch.com/market-research/lysosomal-storagediseases-market/toc
Global Lysosomal Storage Diseases Therapeutics Market 2016-2026
R e s e a r c h
Advent of therapies targeting neuropathic manifestations by crossing blood brain barrier (BBB)
and therapies that overcome immune response and have better tissue selectivity will define the
future landscape of the global lysosomal storage diseases therapeutics market.
Market forecast
The global lysosomal storage diseases therapeutics market has been segmented on the basis of
Indication (Gaucher's Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis,
Others); Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate
Reduction Therapy, Others); End User (Hospitals, Clinics); and Region (North America, Latin
America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA)).
M a r k e t
The Gaucher's Diseases indication segment is estimated to account for 29.7% revenue share of
the global lysosomal storage diseases therapeutics market by 2016 end. The Enzyme
Replacement Therapy segment was valued at US$ 4,833.8 Mn in 2015 and is expected to
exhibit the highest CAGR of 10.0% over the forecast period to reach US$ 13.58 Bn by 2026 end.
The Hospitals end user segment is expected to witness 2.8X increase in revenue over the
forecast period and is expected to create absolute $ opportunity of US$ 346.2 Mn in 2017 over
2016.
Download Sample Report @ http://www.persistencemarketresearch.com/samples/3145
Among regions, Europe is expected to be the dominant regional market in the global lysosomal
P e r s i s t e n c e
storage diseases therapeutics market during the forecast period. The Europe market accounted
for the highest revenue share of 34.8% and was valued at US$ 1,773.2 Mn in 2015; and is
expected to witness a CAGR of 10.2% during the forecast period. North America is expected to
be the second most lucrative market in the global lysosomal storage diseases therapeutics
market and is estimated to represent absolute $ opportunity of US$ 159.6 Mn in 2017 over 2016.
Browse Complete Report @ http://www.persistencemarketresearch.com/market-
research/lysosomal-storage-diseases-market.asp
Shire PLC, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor
Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc. are some of
the companies operating in the global lysosomal storage diseases therapeutics market. Top
market players are investing in focused R&D initiatives to develop innovative products for the
treatment of rare diseases and are looking to drive growth in established markets through
Global Lysosomal Storage Diseases Therapeutics Market 2016-2026
R e s e a r c h
strategic partnerships, collaborations, and acquisitions. The report discusses individual
strategies of these companies in terms of increasing focus on rare diseases, initiatives to
increase awareness, and enhancing distribution base. The report concludes with strategic
recommendations for players already present in the market and new players planning to enter
the global lysosomal storage diseases therapeutics market.
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a
M a r k e t
unique collaboration of data analytics and market research methodology to help businesses
achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying
real-time data collection, big data, and customer experience analytics, we deliver business
intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized solutions to
cater to client-specific needs, and consulting services to offer more value addition. Our nextgeneration research approach for exploring emerging technologies has allowed us to solve the
P e r s i s t e n c e
most complex problems of clients. We do not follow a reactive approach, but a pro-active one.
Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and
provide the latest insights into these technologies when they are being commercialized. Our
ground-breaking approach allows us to deliver market solutions before the technologies reach
the market.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing
startups. PMR’s collaborative environment is committed to building industry-specific solutions by
transforming data from multiple streams into a strategic asset.
Contact Us:
Persistence Market Research
Global Lysosomal Storage Diseases Therapeutics Market 2016-2026
Tel: +1-518-618-1030
Email: [email protected]
Website: http://www.persistencemarketresearch.com/
[email protected]
Stay updated with our official Blog: http://pmrblog.com
P e r s i s t e n c e
M a r k e t
R e s e a r c h
90 Sate Street, Suite 700 Albany, NY 12207
Global Lysosomal Storage Diseases Therapeutics Market 2016-2026